Pharmacy Times August 8, 2024
Denileukin diftitox-cxdl is the only therapy approved for cutaneous T-cell lymphoma that targets IL-2 receptors in malignant T-cells and Tregs.
The FDA approved denileukin diftitox-cxdl (Lymphir; Citius Pharmaceuticals), a novel immunotherapy, for the treatment of relapsed or refractory (R/R) cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy. This is the only CTCL therapy that targets IL-2 receptors in malignant T-cells and Tregs and is the first indication for denileukin diftitox-cxdl.1
“As a treating oncologist, I have seen the profound negative effect on the quality of life in patients with R/R CTCL,” said Francine Foss, MD, professor of hematology and director of the Multidisciplinary T-cell Lymphoma Program at Yale Cancer Center, in a news release. “Given the long-term...
Today's Sponsors
Today's Sponsor